Cell Cycle

Cell cycle is the entire process of cell division from the completion of one division to the end of the next division and is divided into two phases: interphase and division. Life is a continuous process passed from generation to generation and is therefore a process of constant renewal and starting from scratch. Thus, it is a process of constant renewal and starting from scratch. The life of a cell begins with the division of its parent cell and ends with the formation of its daughter cells, or the death of the cell itself. Usually, the formation of daughter cells is considered to mark the end of cell division. The cell cycle is the process from the formation of daughter cells at one cell division to the formation of daughter cells at the next cell division. During this process, the genetic material of the cell is copied and distributed equally to the two daughter cells.

Cat. No.	Product name
BP13109	CDK4/6-IN-2
BP13109	CDK4/6-IN-2 is a potent CDK4 and CDK6 inhibitor (IC50s: 2.7 and 16 nM) extracted from patent US20180000819A1 (Compound 1).
BP13110	CDK4/6-IN-3
BP13110	CDK4/6-IN-3 is a brain-penetrant CDK4/CDK6 inhibitor (Kis: <0.3 nM and 2.2 nM) used for the treatment of glioblastoma. It inhibits CDK1 with a Ki of 110 nM.
BP13111	CDK4/6-IN-6
BP13111	CDK4/6-IN-6 is a potent CDK4/CDK6 inhibitor with Ki of 0.6 nM and 13.9 nM for CDK4/Cyclin D1 and CDK6/Cyclin D3, respectively.
BP13112	CDK8/19-IN-1
BP13112	CDK8/19-IN-1 is a selective and oral bioavailable CDK8/19 dual inhibitor (IC50s: 0.46 nM, 0.99 nM, and 270 nM for CDK8, CDK19, and CDK9).
BP13113	CDK8-IN-1
BP13113	CDK8-IN-1 is a selective CDK8 inhibitor (IC50: 3 nM).
BP13114	CDK8-IN-4
BP13114	CDK8-IN-4 is an inhibitor of CDK8 (IC50: 0.2 nM).
BP13115	CDK9-IN-1
BP13115	CDK9-IN-1 is a novel, selective CDK9 inhibitor for the treatment of HIV infection (IC50: 39 nM for CDK9/CycT1).
BP13116	CDK9-IN-10
BP13116	CDK9-IN-10 is a potent CDK9 inhibitor and the ligand for the PROTAC CDK9 degrader-2.
BP13117	CDK9-IN-11
BP13117	CDK9-IN-11 is a potent CDK9 inhibitor and the ligand for the PROTAC CDK9 degrader-1.
BP13118	CDK9-IN-2
BP13118	CDK9-IN-2 is a special CDK9 inhibitor extracted from patent WO/2012131594A1 (compound CDKI(8)) and has an IC50 of 5 nM and 7 nM in A2058 skin cell line (72 hours) and H929 multiple myeloma cell line (72 hours), respectively.
BP13119	CDK9-IN-7
BP13119	CDK9-IN-7 is a highly selective and orally active CDK9/cyclin T inhibitor (IC50: 11 nM), which exhibits more potent over other CDKs (CDK4/cyclinD: 148 nM; CDK6/cyclinD: 145 nM).
BP13120	CDK9-IN-8
BP13120	CDK9-IN-8 is a highly potent and selective CDK9 inhibitor (IC50: 12 nM).
BP13121	CDK9-IN-9
BP13121	CDK9-IN-9 is a potent and selective CDK9 inhibitor (IC50: 1.8 nM) with anti-cancer activity. It inhibits CDK2 (IC50: 155 nM).
BP13122	CDK-IN-2
BP13122	CDK-IN-2 is a potent and specific CDK9 inhibitor (IC50: <8 nM).
BP13123	CeMMEC1
BP13123	CeMMEC1 is an inhibitor of BRD4, and also has a great affinity for TAF1(IC50=0.9 μM).
BP13124	CeMMEC13
BP13124	CeMMEC13 is an isoquinolinone that selectively inhibits the second bromodomain of TAF1 (IC50 = 2.1 μM).
BP13125	Centrinone
BP13125	Centrinone (LCR-263) is a reversible inhibitor of polo-like kinase 4 (PLK4; Ki:0.16 nM).
BP13126	Centrinone-B
BP13126	Centrinone-B (LCR-323) is a potent and highly selective inhibitor of PLK4 (Ki: 0.59 nM).
BP13127	Cerevisterol
BP13127	Cerevisterol is a cytotoxic steroid, can inhibit the activity of DNA polymerase alpha. It can stimulate NGF-mediated neurite outgrowth on PC12 cells. Cerevisterol acts as a natural agent for treating inflammatory diseases by targeting an MAPK, NF-κB, AP-1, and Nrf2-mediated HO-1 signaling cascade.
BP13128	Cetraxate hydrochloride
BP13128	Cetraxate HCl is an oral gastrointestinal medication. It has a cytoprotective effect.